Berlin-Chemie

Focus: Berlin-Chemie is a legacy German pharmaceutical company founded in 1886 focused on small molecule development across cardiovascular, oncology, metabolic, and neurology therapeutic areas. The company operates as a mid-cap biotech with a diversified pipeline but limited publicly available scale metrics.

Cardiovascular Oncology Metabolic Diseases Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Berlin-Chemie

AI assessmentNot Hiring

No open roles listed right now. Follow Berlin-Chemie to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

INPUT

Diabetes Mellitus

N/A

Clinical Trials (1)

NCT02868931Evaluation of a Diabetes Treatment and Education Program for Insulin Pump Therapy (INPUT)

N/A

Help build intelligence for Berlin-Chemie

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

138-year heritage with established infrastructure and European market presence in cardiovascular and metabolic diseases
Diversified pipeline spanning Phase 1–Phase 4 programs including Phase 3 assets (Bemiparin sodium, Nebilet, Elacestrant) with near-term regulatory potential
Small-molecule specialty focus provides deep chemistry and pharmacology expertise for drug development professionals

Watch Out For

Currently 0 active job openings publicly listed, suggesting minimal or frozen hiring despite pipeline activity
Sparse public clinical trial data (only 2 total active trials) and no publications reported indicate low research visibility or disclosure

Generated by Claude from Berlin-Chemie's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Continuous glucose monitoring

Stress

N/A

Systematic detection of vascular risk factors and subsequent evidence-based treatment

Stroke

N/A

Torasemide tablet 10 mg

Healthy Adult Male and Female Volunteers

Phase 1

Levothyroxin

Healthy

Phase 1